These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22042473)

  • 1. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.
    Fendrich V; Wiese D; Waldmann J; Lauth M; Heverhagen AE; Rehm J; Bartsch DK
    Ann Surg; 2011 Nov; 254(5):818-23; discussion 823. PubMed ID: 22042473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
    Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
    Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedgehog inhibition with cyclopamine represses tumor growth and prolongs survival in a transgenic mouse model of islet cell tumors.
    Fendrich V; Rehm J; Waldmann J; Buchholz M; Christofori G; Lauth M; Slater EP; Bartsch DK
    Ann Surg; 2011 Mar; 253(3):546-52. PubMed ID: 21239987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
    D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
    Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
    Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
    J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
    Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN
    PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoothened antagonists reverse taxane resistance in ovarian cancer.
    Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
    Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.
    Feldmann G; Fendrich V; McGovern K; Bedja D; Bisht S; Alvarez H; Koorstra JB; Habbe N; Karikari C; Mullendore M; Gabrielson KL; Sharma R; Matsui W; Maitra A
    Mol Cancer Ther; 2008 Sep; 7(9):2725-35. PubMed ID: 18790753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer.
    Hwang RF; Moore TT; Hattersley MM; Scarpitti M; Yang B; Devereaux E; Ramachandran V; Arumugam T; Ji B; Logsdon CD; Brown JL; Godin R
    Mol Cancer Res; 2012 Sep; 10(9):1147-57. PubMed ID: 22859707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
    Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
    Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel synthetic smoothened antagonist transiently inhibits pancreatic adenocarcinoma xenografts in a mouse model.
    Strand MF; Wilson SR; Dembinski JL; Holsworth DD; Khvat A; Okun I; Petersen D; Krauss S
    PLoS One; 2011; 6(6):e19904. PubMed ID: 21698280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
    Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
    Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition.
    Chang Q; Foltz WD; Chaudary N; Hill RP; Hedley DW
    Int J Cancer; 2013 Jul; 133(1):225-34. PubMed ID: 23280784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonists.
    Lucas BS; Aaron W; An S; Austin RJ; Brown M; Chan H; Chong A; Hungate R; Huang T; Jiang B; Johnson MG; Kaizerman JA; Lee G; McMinn DL; Orf J; Powers JP; Rong M; Toteva MM; Uyeda C; Wickramasinghe D; Xu G; Ye Q; Zhong W
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3618-22. PubMed ID: 20493695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hedgehog pathway and pancreatic cancer.
    Hidalgo M; Maitra A
    N Engl J Med; 2009 Nov; 361(21):2094-6. PubMed ID: 19923581
    [No Abstract]   [Full Text] [Related]  

  • 16. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer.
    Feldmann G; Habbe N; Dhara S; Bisht S; Alvarez H; Fendrich V; Beaty R; Mullendore M; Karikari C; Bardeesy N; Ouellette MM; Yu W; Maitra A
    Gut; 2008 Oct; 57(10):1420-30. PubMed ID: 18515410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis.
    Ruiz-Heiland G; Horn A; Zerr P; Hofstetter W; Baum W; Stock M; Distler JH; Nimmerjahn F; Schett G; Zwerina J
    Ann Rheum Dis; 2012 Mar; 71(3):400-7. PubMed ID: 22233602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease.
    Zerr P; Palumbo-Zerr K; Distler A; Tomcik M; Vollath S; Munoz LE; Beyer C; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
    Blood; 2012 Oct; 120(14):2909-17. PubMed ID: 22915638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts.
    Walter K; Omura N; Hong SM; Griffith M; Vincent A; Borges M; Goggins M
    Clin Cancer Res; 2010 Mar; 16(6):1781-9. PubMed ID: 20215540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
    Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
    Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.